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Objectives: to identify the prevalence, and describe the management of, neutropenia throughout 
the chemotherapy treatment among women with breast cancer. Methods: observational study, 
cycles of chemotherapy. 116 neutropenic events were recorded, and 63.3% of the patients 
presented neutropenia at some point of their treatment, 46.5% of these presenting grade II. 
The management used was temporary suspension between the cycles and the mean number 
of delays was 6 days. The study was prospective and longitudinal, where the evaluation of the 
hematological toxicities was undertaken at each cycle of chemotherapy, whether neoadjuvant or 
adjuvant. Results: 79 women were included, who received 572 cycles. However, the reasons for 
the suspensions were the lack of a space in the chemotherapy center, followed by neutropenia. 
Conclusion: neutropenia is one of the most common and serious adverse events observed 
during the chemotherapy. Nursing must invest in research regarding this adverse event and in 
management strategies for organizing the public health system, so as to offer quality care.
Descriptors: Nursing; Breast Neoplasms; Drug Therapy/adverse effects.
Neutropenia: occurrence and management in
women with breast cancer receiving chemotherapy
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Introduction
Neutropenia is characterized by the reduction 
in white blood cells, with a neutrophil count of below 
1.5x109/L. The occurrence of this event varies from 16% 
to 81% among the patients who receive chemotherapy 
treatment(1-3).
It is one of the principal adverse events (AE) of 
antineoplastic chemotherapy, and is the one which 
interferes most in the dosage of the chemotherapy 
agents. The occurrence of neutropenia is associated 
with an increase in mortality, morbidity and treatment 
costs, in addition to the impossibility of predicting which 
patients will present it(4-5).
The management of this chemotherapy-induced AE 
is administered in different ways in clinical practice. In 
general, the strategies are limited to the reduction of 
the dose of the chemotherapy agents, postponement 
between the cycles, and the use of colony-stimulating 
factors, although these are considered common clinical 
practices during the treatment of patients with primary 
breast cancer who present AEs, such as episodes of 
neutropenia(6).
In spite of these strategies being widely used, 
clinical studies have shown that these modifications 
in the dosage or in the time scheduled can have as a 
consequence an inferior result in the final quality of the 
therapy(7).
The efficacy of the assistance and the treatment 
given to the patient are fundamental for the quality of 
the health care. The occurrence of neutropenia indicates 
the need for nursing to define protocols for evaluation 
and follow-up, which includes the AEs, the degrees of 
compromise, and their management(1).
The standards of neutropenia management vary 
from one health center to another.  The development 
of nursing care protocols for the management of 
chemotherapy-induced neutropenia may allow more 
patients to benefit from: treatment with the complete 
dose undertaken within the schedule; reduction in 
variety of conduct in the assistance provided; promotion 
of the efficacious use of colony-stimulating factor; help 
in taking decisions regarding contradictory situations; 
and, principally, from improvement in the quality of the 
care for the patient, which leads to improvement in the 
results of the treatment(8).
In the Gynecologic Oncology and Mastology 
outpatient clinic of the Hospital das Clínicas, University 
of São Paulo at Ribeirão Preto, Medical Faculty, of the 
(HCFMRP-USP), there are no nursing care protocols 
for attending women with gynecological or breast 
cancer during their treatment, which makes it difficult 
to standardize the guidance and information provided 
to the woman and her caregivers by the nursing team. 
In the women’s accounts, one can observe divergent 
or very often contradictory information. This hinders 
decision-making regarding the AEs of the chemotherapy 
treatment and the building of trust in the team. One may 
also note the absence of Brazilian studies directed at the 
management of neutropenia in the area of Nursing, as 
well as the implementation of specific protocols which 
help in improving the quality of the care given. 
In the light of the above, this study’s objective was to 
identify the prevalence of, and describe the management 
of, neutropenia throughout the chemotherapy treatment 
among women with breast cancer. 
Method
This study is part of the project titled “Evaluation of 
the quality of life, anxiety, depression and toxicity to the 
chemotherapy treatment in women with breast cancer”, 
approved by the HCFMRP-USP’s Ethics Committee, 
under Process HCRP 1460/2009.
Focussing on chemotherapy-induced neutropenia, 
an observational, longitudinal and prospective study 
was undertaken, evaluating this AE at each cycle of 
chemotherapy whether neodjuvant or adjuvant, in 
women with breast cancer under treatment at the 
Mastology Outpatient Center of the Teaching Hospital of 
the Ribeirão Preto Faculty of Medicine of the University 
of São Paulo (HCFMRP-USP).
Based on a calculation of 100 new cases/year 
of breast cancer attended in the above-mentioned 
outpatient center, the study recruited all the women 
who started chemotherapy treatment in the period April 
2009 – March 2010, with the inclusion criteria: women 
aged over 19 years old with a diagnosis of breast cancer; 
who were beginning chemotherapy treatment for the 
first time, neoadjuvant or adjuvant. The following were 
considered exclusion criteria: women who could not 
express themselves without the help of another person, 
who presented metastatic disease at diagnosis or during 
the treatment, who presented another malignant tumor 
at diagnosis, who had previously been treated for breast 
cancer or for another type of malignant tumor, and 
women in the puerperal stage of pregnancy.
The study included 83 women with breast cancer, 
who had started neoadjuvant or adjuvant chemotherapy 
treatment. There were no refusals to participate; 
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however, during the follow up, two women abandoned 
the chemotherapy treatment due to intolerance of the 
AEs, one requested to be excluded from the research, 
and one was diagnosed with metastasis. As a result, the 
sample was made up of 79 women. 
For data collection, an instrument was used with 
information on identification, data on the diagnosis, the 
result of the complete blood counts (CBCs) undertaken 
prior to each cycle of chemotherapy, the dosage of 
the chemotherapy agents used in the neoadjuvant 
and adjuvant settings, data of possible episodes of 
hospitalization during the chemotherapy treatment and, 
also, data on the surgical procedure. This information 
was collected at each cycle in interviews with the women 
participating, as was complementary information such as 
the results of tests, obtained from their hospital records. 
Neutropenia and the socio-demographic variables of 
age, race, co-morbidity and the staging of the cancer 
were defined as the study’s variables. 
Based on the study’s objectives, descriptive 
analysis (frequency, mean, median and standard 
deviation) of all the variables was undertaken, as was 
the descriptive analysis (frequency, mean, median and 
standard deviation) of the variable neutrophil, for each 
cycle.   IBM, Armonk, NY, U.S.A.) was used for this.
Results
Among the 79 women who participated, the age 
varied from 29 to 69 years old, with 34.2% falling into 
the age range of 51 to 60 years old, and 24.1% being 
aged below 40 years old. The participants’ mean age 
was 48.4 years old, with a standard deviation of 9.67 
years (Table 1).
Considering the clinical stages of breast cancer 
presented, the most observed was IIa in 25.3% of the 
women, followed by IIb and IIIb with a frequency of 
21.5% for each one (Table 1).
In relation to the therapy used, 50.6% of the women 
received neoadjuvant chemotherapy treatment, while 
49.4% received adjuvant chemotherapy treatment. The 
chemotherapy protocols used, both for the neoadjuvant 
treatment and the adjuvant, were FEC (Fluorouracil, 
Epirubicin and Cyclophosphamide), EC-T (Epirubicin, 
Cyclophosphamide and Paclitaxel), EC-TH (Epirubicin, 
Cyclophosphamide, Paclitaxel and Trastuzumab) and 
EC (Epirubicin and Cyclophosphamide). The choice 
of scheme is made in line with the institution’s 
protocol, which stipulates as criteria the definition of 
the clinical staging and the histological diagnosis, as 
Table 1 - Distribution of women who received 
chemotherapy for breast cancer, by age, staging of the 
disease and nutritional status. Ribeirão Preto, State of 
São Paulo (SP), Brazil, 2010 (N=79)
Characteristic Number and percentage (%) of women
Age
Below 30 years old 1 (1.3%)
31 to 40 years old 18 (22.8%)
41 to 50 years old 25 (31.6%)
51 to 60 years old 27 (34.2%)
61 to 69 years old 8 (10.1%)
Staging of the disease
In situ 2 (2.5%)
Ia 5 (6.3%)
IIa 20 (25.3%)
IIb 17 (21.5%)
IIIa 15 (19%)
IIIb 17 (21.5%)
No record 3 (3.8%)
Body composition
Below weight (< 18.5Kg/m2) 1 (1%)
Normal weight (18.5-24.99Kg/m2) 17 (22%)
Overweight (≥ 25Kg/m2) 31 (41%)
Obesity (≥ 30Kg/m2) 27 (36%)
well as the immunohistochemical panel for hormone 
receptors and HER2/neu.
A total of 572 chemotherapy cycles was undertaken, 
with 301 cycles for neoadjuvant treatment and 271 
for adjuvant treatment. During the undertaking of 
the 572 chemotherapy cycles, various complications 
were identified, which directly influenced the duration 
of the treatment. Of the 79 women studied, 30.4% 
were hospitalized during the treatment, totalling 30 
hospitalizations, excluding the hospitalizations caused by 
undertaking complementary tests or surgical procedures. 
It stands out that 33.33% (10 hospitalizations) were 
due to febrile neutropenia, eight to dehydration, two to 
urinary tract infections, two to pneumonia, and eight 
were for other reasons.
 According to the hematological tests collected 
prior to each cycle of chemotherapy, of the 79 women 
who participated in the study, 63.3% presented 
neutropenia at some point during the chemotherapy 
treatment. Of these, 16.5% developed the event just 
once, 20.2% presented neutropenia twice during the 
chemotherapy, 16.5% three times, and 10.1% had four 
neutropenic episodes.
The occurrence of neutropenia was observed both 
in neoadjuvant treatment and in adjuvant treatment. 
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Of the 40 women who received the neoadjuvant 
treatment, 24 (60%) developed neutropenia at some 
point of the chemotherapy, which represented 48% of 
all the neutropenic episodes verified in the study. In the 
adjuvant treatment, greater occurrence of neutropenia 
was observed, as, among the 39 participants, it was 
presented by 26 (66.7%), representing 52% of the 50 
neutropenic events.
According to the chemotherapy protocol, 31 
women used EC-T/EC-TH, of whom 67.7% developed 
neutropenia. Among the 48 patients treated with FEC/
EC, on the other hand, 60.4% presented neutropenia.
A total of 116 neutropenic episodes was observed 
during the study. Of these, 9.5% were classified as 
grade I, 46.5% grade II, 31.9% grade III and 12.1% 
as grade IV. The hematological results obtained prior 
to initiating the third cycle of chemotherapy showed a 
greater occurrence of neutropenic events (23.3%) in 
this stage of the treatment (Table 2).
The highest number of occurrences of grades III 
and IV neutropenia was observed in the tests made prior 
to the third cycles (32.4%) and the highest number of 
occurrences of neutropenia grade IV, in the tests which 
preceded the second cycles (42.8%), indicating the need 
for continuous evaluation of symptoms, and vigilance 
during this phase of the treatment. 
The mean age of the women who presented 
neutropenia grade III at some point of their treatment 
was 49.63 years old, while that of those who presented 
grade IV was 43.2 years old. The BMI of the patients 
who presented grade III and grade IV of neutropenia 
was 28.3Kg/m2 and 28.5Kg/m2, respectively.
Table 2 - Neutropenic episodes observed in women with breast cancer who received chemotherapy treatment, by the 
grade of neutropenia and cycle of chemotherapy. Ribeirão Preto, SP, Brazil, 2010
Table 3 - Distribution of the women who received chemotherapy for breast cancer, by reason for the delay between 
the cycles. Ribeirão Preto, SP, Brazil, 2010 (N=48)
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle7 Cycle 8 Total (%)
Grade I 0 2 1 2 2 2 2 0 11 (9.5%)
Grade II 0 6 12 13 15 6 0 2 54 (46.5%)
Grade III 0 7 12 8 8 2 0 0 37 (31.9%)
Grade IV 0 6 2 1 1 4 0 0 14 (12.1%)
Total 0 21 27 24 26 14 2 2 116 (100%)
Reason for delay for the 
EC-T/EC-TH Protocol
Cycle 2 
(n=48)
Cycle 3 
(n=48)
Cycle 4 
(n=48)
Cycle 5 
(n=48)
Cycle 6 
(n=47)
Cycle 7 
(n=46)
Cycle 8 
(n=42) Total
Lack of a space 8 11 11 7 8 3 1 49
Neutropenia 7 10 10 12 1 0 2 42
Infection 1 1 1 1 0 0 1 5
Others 6 7 8 7 11 18 6 63
Total 22 29 30 27 20 21 10 159
Neutropenia was responsible for the temporary 
suspension of the treatment in 42 cycles of the 159 
undertaken by women who used the EC-T/ EC-TH 
protocols, and of the 118 cycles of FEC/EC, 44 were 
not administered in the space of time stipulated by the 
protocol, for the same reason.
Delays occurred between the cycles of 
chemotherapy, the mean being 6.3 days.  It stands out 
that the cycles’ delays did not occur solely due to the 
management of neutropenia, being also related to the 
management of the health system, with a lack of spaces 
in the chemotherapy center. In spite of this difference 
– between the management of the neutropenia 
and the management of the health system – the 
authors present the reasons for the delays grouped 
in line with the chemotherapy protocol received by 
the participant.
According to the data presented in Tables 3 and 4, 
the lack of spaces in the Chemotherapy Center took first 
place, and neutropenia the second, among the reasons 
for delays between the chemotherapy cycles. 
Another possibility for managing neutropenia, 
reduction in the dose, was observed in this study only for 
one participant. Other possible means of management, 
such as the use of colony-stimulating factors, 
were not used.
305
www.eerp.usp.br/rlae
Nascimento TG, Andrade M, Oliveira RA, Almeida AM, Gozzo TO.
Table 4 - Distribution of the women who received chemotherapy for breast cancer, by reason for the delay between 
the cycles. Ribeirão Preto, SP, Brazil, 2010 (N=31)
Reason for the delay for the FEC/EC Protocol Cycle 2 (n=31)
Cycle 3 
(n=31)
Cycle 4 
(n=31)
Cycle 5 
(n=31)
Cycle 6 
(n=31)
Total 
Number
Neutropenia 7 10 10 8 9 44
Lack of a space 8 11 11 2 1 33
Infection 1 1 1 1 0 4
Others 6 7 8 7 9 37
Total 22 29 30 18 19 118
Discussion
The development of myelosuppression during 
chemotherapy is influenced as much by the characteristics 
of the drugs used as by the conditions presented by the 
patient. Therefore, the association of myelotoxicity with 
the activity of the treatment is not always direct(9). 
Although the risk factors for neutropenia during 
chemotherapy treatment are not well defined, current 
studies point to: advanced age (≥65 years), female sex, 
low performance status and nutritional status, reduced 
body surface area, reduction in blood cell count prior to 
starting treatment (reduced number of lymphocytes and 
of hemoglobin) and previous involvement of the bone 
marrow(4,10).
The mean age of patients who participate in 
randomized clinical trials varies from 46 to 49 years old 
and is similar to that found in this study. However, it 
was possible to observe that the percentage of young 
women, from 31 to 40 years old, with mammary 
neoplasms has increased considerably, representing 
22.8% in the sample studied. However, it stands out 
that in current studies the authors present the mean age 
of all the participants, without distinguishing between 
the age ranges which present neutropenia during the 
treatment or not(2,11-12).
Regarding the choice, use and activity of the 
drugs, current data indicates that both for adjuvant and 
neoadjuvant treatment of breast cancer, chemotherapy 
regimens based on anthracyclines and taxanes are 
considered first choice. The introduction of the taxanes 
and the increase in the doses of the anthracyclines favor 
greater occurrence of myelotoxicities, resulting in the 
risk of febrile neutropenia and infections during the 
treatment(13).
Neutropenia is the event which most influences the 
limit of the dosage of the chemotherapy agent and the 
scheduling of the cycles during the treatment. Patients 
who present chemotherapy-induced neutropenia have 
a risk of potentially fatal infections. Although the 
reduction of the dose of chemotherapy or the delay of 
the subsequent cycle of treatment and, consequently, 
the reduction of the relative dose intensity, can limit the 
myelotoxicity, these actions can also impact negatively 
on the result of the treatment, and must be avoided(14).
These delays or reductions of dose minimize the 
toxic sequelae of the treatment in patients whose 
blood count has not recovered appropriately. Such 
practices can have a significant impact on the survival 
results, in the same way that they reduce the intensity 
of the dose received. However, in order to obtain the 
maximum benefit from the chemotherapy treatment, 
the maintenance of the total dose calculated must 
be maintained as an important response factor to 
the treatment, as for every seven days of delay in 
the chemotherapy treatment, there is a reduction of 
approximately 5% of the intensity of the dose(6).
A limited number of studies has shown that the 
absence of myelotoxicity during the chemotherapy is 
associated with a worse prognosis, which suggests that 
myelodepression may represent an important biological 
marker for the effect of the treatment. In addition to 
this, other researchers have emphasized the potential 
importance of adapting the chemotherapy dose based 
on the hematological toxicity, as the absence of this 
may be the result of underdosage. However, prospective 
studies are necessary to evaluate whether the dosage of 
the drug, guided by the occurrence of toxic effects, can 
improve the efficacy of standard regimes(10,15).
Furthermore, the direct effects caused during the 
treatment, and the chemotherapy-induced neutropenia, 
have a detrimental effect on the patients’ quality of life. 
In clinical practice, so as to reduce the risk of infection, 
the neutropenic patients are instructed to follow strict 
advice, to avoid crowds, not to eat raw fruit/ vegetables 
and to monitor their temperature regularly. Running 
a fever with neutropenia is considered a medical 
emergency, and those who present this event generally 
need hospitalization and treatment with intravenous 
broad-spectrum antibiotics. This being so, the hospital 
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environment, the separation of members of the family 
and the undertaking of invasive procedures, and the fear 
of infection becoming established or of failures occurring 
in the treatment, as well as the feeling of being close to 
death, contribute to a substantial reduction in patients’ 
well-being(16-17).
The present study considered the general 
management of neutropenia, irrespective of the health 
professional who provided it. While emphasizing that 
it was not possible to identify the work undertaken 
by the nursing team among the actions undertaken, 
these remaining centered on the medical team, the 
authors believe that preventing the risk of neutropenic 
complications involves a collaborative approach, with 
the active and direct participation of nurses, the 
patient, and family members. In care directed at the 
neutropenic patient, Nursing is fundamental in the 
rapid and efficacious identification of neutropenia and 
the other events which can occur, and in ensuring 
the continuity of the care provided. In this way, 
it falls to the nurse to advise the patients and their 
family members on the consequences of neutropenia 
before chemotherapy is started, warning them about 
the importance of adhering to the planned dose and 
treatment schedule, the need to attend consultations, 
laboratory monitoring, and the administration of growth 
factor, if necessary(9).
Oncology nursing, in addition to providing safety 
to the patients throughout the antineoplastic treatment 
process, aims to increase their life expectancy with 
quality and not only to cure; rather, it aims to assist 
the human being as a whole. Therefore, the assistance 
provide by Nursing in the routine of the care must 
be grounded in the quality work directed towards the 
teaching of self-care, with the objective of protecting the 
autonomy and the improvement of the patients’ quality 
of life, and must allow the recognition and the valuing of 
the professional through the establishment of a positive 
and empathetic relationship between the person who 
cares and the person who is cared for(18).
The need to establish efficient comprehensive care 
for the oncological patient requires great mobilization 
of the entire health system, from the training of the 
professionals who shall provide the direct care to the 
infrastructure of the service that the patient shall use.
In a study which evaluated the management of the 
Nursing service in Brazilian public hospital institutions, 
the nursing team reports satisfaction regarding the care 
given to the client, in relation to the qualification of 
the work, the dedication and the humanization in the 
attendance, and the communication. On the other hand, 
they feel uncomfortable because of the service, which 
lacks adequate facilities and sufficient human resources 
to care, as well as material in adequate quantities, and 
appropriate furniture(19).
In research undertaken in 2008 in the same 
institution as the present study, which evaluated 
72 women with breast cancer in neoadjuvant or 
adjuvant treatment, it was observed that of the 558 
chemotherapy cycles undertaken, there were 152 
delays between the cycles during the treatment. It is 
worth emphasizing that 82 of these delays were caused 
because of alterations detected in the hematological 
tests, while only six were caused by lack of a space in 
the chemotherapy center(20).
Considering the data from the present study, one 
can observe that the number of delays between the 
cycles of chemotherapy resulting from lack of a space 
increased, as, of the 277 delays recorded between the 
cycles of chemotherapy, 82 occurred as a result of the 
lack of a space in the chemotherapy center. It is asked 
whether the service is aware of the number of delays, 
as that presented in this article refers only to the cases 
of breast cancer, and whether the service is prepared to 
receive the increase in demand from the cases of cancer. 
Even with all the advances undertaken in Brazilian 
public health policy, with emphasis on comprehensive 
care for the oncological patients, little has been studied 
regarding the managing of the health services which 
attend this type of patient. This hinders the analysis 
of the suitability of the time periods for undertaking 
the treatment, such as chemotherapy. In the Brazilian 
Technical Bases Manual, it is specified that adjuvant 
chemotherapy should be initiated, at the most, between 
30 and 60 days post-surgery(21). However, the time to be 
waited for undertaking the other chemotherapy cycles is 
not specified. 
The current conditions of saturation in the public 
health services contribute to privation of citizenship, 
both of the service users, who receive health care which 
lacks quality, and of the health workers, who exercise 
their professional activities under inadequate working 
conditions. This process makes both parties vulnerable, 
although in different ways(22).
The health organizations, among these the hospitals, 
as well as the various types of health professional, have 
invested in the search for new management strategies 
which may make it possible to conciliate the reduction 
of costs, the improvement of the quality of the services 
offered, and – principally – the clients’ satisfaction.  
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Conclusion
The occurrence of neutropenia, observed in the 
present study, is in accordance with the results of 
international research. As this is characterized as one 
of the more common and serious AEs which can occur 
during antineoplastic chemotherapy, it is an important 
question to be investigated throughout the treatment.
For decades, Nursing has classified this event as 
one of the principal axes for carrying out research, in 
search of results which may indicate improvement in 
the care given to neutropenic patients. Based on this 
information, it becomes possible for oncological nurses 
to perform a key role in improving the care directed at 
this patient group.    
It is through investing in new management 
strategies able to achieve improvements in the work 
conditions of health professionals and in the organization 
of the public health system that the principal objective 
of the care for oncological patients shall be achieved: 
the offering of quality care, protecting their autonomy, 
recognizing and valuing the professional who assists 
them, and establishing an empathetic relationship 
between both. 
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